Neisvac-C

Tetanus toxoid, algeldrate, and Neisseria meningitidis group C polysaccharide, the active ingredients in Neisvac-C, is a vaccine presented as a vaccine for intramuscular use. It prevents tetanus and provides immunity against Neisseria meningitidis group C infection in individuals at risk. GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neisvac-C is a combination vaccine that targets bacterial toxin and capsular polysaccharide disease pathways. It is indicated for: - Tetanus: induces protective antibodies that neutralize tetanus toxin. - Neisseria meningitidis group C infection: stimulates antibodies against the group C polysaccharide capsule to prevent invasive meningococcal disease. - Travel to endemic regions: provides protection against group C meningococcal disease for travelers and pilgrims.

Neisvac-C is generally well tolerated, but injection‑related reactions and rare systemic events have been reported.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema and edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: transient mild headache. - Fatigue: temporary tiredness. - Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare demyelinating neuropathy. - Seizures: infrequent neurologic events. - Severe hypotension: marked drop in blood pressure. - Persistent high fever: prolonged temperature elevation. - Severe local necrosis: extensive tissue damage at injection site.

Prior to administration, consider the following safety measures: - Pregnancy: safety not established; vaccinate only if benefit outweighs risk. - Breastfeeding: no known adverse effects, but consult a healthcare professional. - Immunocompromised patients: vaccine may elicit reduced immune response. - Known allergy: avoid if hypersensitivity to any vaccine component exists. - Acute illness: postpone vaccination during moderate or severe febrile illness. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by concurrent therapies or other immunizations.

Major Interactions (Avoid): - Live bacterial or viral vaccines: concurrent administration may interfere with immune response. - Immunoglobulin therapy: can neutralize vaccine antigens and diminish effectiveness.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce antibody production. - Antipyretics taken prophylactically: could mask early fever signals. - Blood products administered within 48 hours: may lower vaccine efficacy.